Kyowa Hakko Kirin completes biopharmaceutical API facility at Takasaki

9-Apr-2014

Will contain one of the largest recombinant animal cell bioreactors in Japan

Japanese pharmaceutical company Kyowa Hakko Kirin has completed construction of a GMP biopharmaceutical API manufacturing facility at its Takasaki plant in an investment of approximately JPY6bn (€43m; US$59m).

The 3,892m2 four-storey HA4 facility contains one of the largest bioreactors for recombinant animal cells (12,000L) in Japan, as well as a purification facility with a large column.

The company says the new bioreactor will enable it to offer large scale and stable manufacturing of high-quality pharmaceutical ingredients.

Sign up for your free email newsletter

Operations will commence at the new facility in the first half of 2016.